Indivior Pharmaceuticals (INDV) Long-Term Investments (2022 - 2026)

Indivior Pharmaceuticals' Long-Term Investments history runs 5 years deep, the most recent figure standing at $27.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments changed 0.0% year-over-year to $27.0 million; the TTM figure through Mar 2026 stood at $27.0 million (changed 0.0% YoY), while the FY2025 annual figure was $28.0 million, up 3.7% from the prior year.
• Long-Term Investments for Q1 2026 stood at $27.0 million, down from $28.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $98.0 million in Q4 2022, with the low at $27.0 million in Q4 2024.
• The 5-year median for Long-Term Investments is $27.5 million (2024), against an average of $37.9 million.
• The sharpest annual moves came in 2023 and 2025: Long-Term Investments tumbled 58.16% in 2023, then grew 3.7% in 2025.
• Indivior Pharmaceuticals' Long-Term Investments stood at $98.0 million in 2022, then sank by 58.16% to $41.0 million in 2023, then plunged by 34.15% to $27.0 million in 2024, then advanced by 3.7% to $28.0 million in 2025, then dropped by 3.57% to $27.0 million in 2026.
• Business Quant data shows INDV's Long-Term Investments at $27.0 million in Q1 2026, $28.0 million in Q4 2025, and $28.0 million in Q3 2025.